Sage Therapeutics, Inc. announced that, on July 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 14,700 shares of its common stock, and 4,450 performance restricted stock units to six new employees under Sage’s 2016 Inducement Equity Plan.
July 3, 2019
· 2 min read